BIO.News Newsletter

Happy Friday. Before you get into weekend mode, we’ve got news on the animal biotech turf war in Washington—but if you’re already there, grab another cup of coffee and kick back with our two new videos recapping the BIO CEO & Investor Conference.  Here are about 800 words, which you can read in 4 minutes.

What did you think of last night’s debate in Nevada? Did Bloomberg kill it—or did Warren kill his campaign? Tweet us your thoughts at @IAmBIOtech. (And if you missed it, here are some takeaways from the AP.)  In the meantime, here are about 800 words (4 minutes) on the outlook for Bayh-Dole and new cures and the outlook for the bioeconomy.

We’re midway through the short week, with news on what we can expect from the EPA on biofuels requirements as well as the outlook for Grassley-Wyden when Congress returns from recess. Plus, a highly respected doctor explains why proposed drug price controls will disincentivize R&D. Here are 800 words (4 minutes).

We’re midway through the short week, with news on what we can expect from the EPA on biofuels requirements as well as the outlook for Grassley-Wyden when Congress returns from recess. Plus, a highly respected doctor explains why proposed drug price controls will disincentivize R&D. Here are 800 words (4 minutes).

We hope you enjoyed a day off. Congress isn’t back yet, but we are, with a look at how precision ag is being used on farms as well as a White House study that seems to be in direct opposition to some policies being proposed by the same White House. Here are around 900 words, which you can read in 4 and a half minutes.

Happy Valentine’s Day! After a busy week, we’re taking a look at how biotechnology will affect everything from the chocolate and flowers you might give or receive today, to, quite literally, the health of human hearts, in a quick 688 words, or 3 and a half minutes. We’re taking Monday off for Presidents’ Day. We’ll be back on Tuesday, February 18, with regularly scheduled programming.

If you missed the BIO CEO & Investor Conference this week, you can find recaps on our blog. But now, we’re back in Washington, with some insight into what’s going on with animal biotech regulation at FDA as well as some breaking news on the coronavirus, in about 960 words, just under 5 minutes.

Day #2 of the BIO CEO & Investor Conference was about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like, especially in an election year? How can we incentivize innovation? Here are some takeaways in just over 1,000 words, just over 5 minutes. (Read to the end for news on Grassley-Wyden and other things happening in Congress, too.)

The President’s budget was released yesterday (Monday, February 10)—and everyone was waiting for details on the international price index or other plans around drug pricing. The good news: the budget didn’t mention IPI specifically, or any foreign reference pricing policy, for that matter. The not-so-good news: there’s still a lot of uncertainty around what will happen with drug pricing. So, what is in the budget? Here’s what you need to know, in a special edition of Good Day BIO. (And it's…

We’re seeing an “extraordinary level” of biotech innovation, said BIO Chair Jeremy Levin, CEO of Ovid Therapeutics Inc., while kicking off the 22nd BIO CEO & Investor Conference on February 10th in New York. Day #1 of the conference featured discussions on the breakthrough therapies of the future. But alongside the exciting science are very real challenges: low public perception of the industry, political chaos, industry consolidation geopolitical challenges, and of course, incentivizing the…